149 related articles for article (PubMed ID: 26121954)
1. The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Jo KW; Yoon S; Song JW; Shim TS; Lee SW; Lee JS; Kim DY; Lee JH; Lee JH; Choi Y; Lee KH
Int J Hematol; 2015 Sep; 102(3):357-63. PubMed ID: 26121954
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
[TBL] [Abstract][Full Text] [Related]
3. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
Bergeron A; Chevret S; Granata A; Chevallier P; Vincent L; Huynh A; Tabrizi R; Labussiere-Wallet H; Bernard M; Chantepie S; Bay JO; Thiebaut-Bertrand A; Thepot S; Contentin N; Fornecker LM; Maillard N; Risso K; Berceanu A; Blaise D; Peffault de La Tour R; Chien JW; Coiteux V; Socié G;
JAMA; 2017 Aug; 318(6):557-566. PubMed ID: 28787506
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Ahn JH; Jo KW; Song JW; Shim TS; Lee SW; Lee JS; Kim DY; Lee JH; Lee JH; Choi Y; Lee KH
Clin Transplant; 2015 Dec; 29(12):1133-9. PubMed ID: 26383085
[TBL] [Abstract][Full Text] [Related]
5. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.
Duque-Afonso J; Ihorst G; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Prasse A; Marks R
Bone Marrow Transplant; 2013 Aug; 48(8):1098-103. PubMed ID: 23376822
[TBL] [Abstract][Full Text] [Related]
6. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.
Lam DC; Lam B; Wong MK; Lu C; Au WY; Tse EW; Leung AY; Kwong YL; Liang RH; Lam WK; Ip MS; Lie AK
Bone Marrow Transplant; 2011 Dec; 46(12):1551-6. PubMed ID: 21317934
[TBL] [Abstract][Full Text] [Related]
7. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation.
Nakasone H; Kanda J; Yano S; Atsuta Y; Ago H; Fukuda T; Kakihana K; Adachi T; Yujiri T; Taniguchi S; Taguchi J; Morishima Y; Nagamura T; Sakamaki H; Mori T; Murata M;
Transpl Int; 2013 Jun; 26(6):631-9. PubMed ID: 23551210
[TBL] [Abstract][Full Text] [Related]
8. Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning.
Duque-Afonso J; Ihorst G; Waterhouse M; Zeiser R; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Marks R; Prasse A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2277-2284. PubMed ID: 29964193
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gazourian L; Rogers AJ; Ibanga R; Weinhouse GL; Pinto-Plata V; Ritz J; Soiffer RJ; Antin JH; Washko GR; Baron RM; Ho VT
Am J Hematol; 2014 Apr; 89(4):404-9. PubMed ID: 24375545
[TBL] [Abstract][Full Text] [Related]
10. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Williams KM; Cheng GS; Pusic I; Jagasia M; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Chien JW; Jacobsohn DA; Pavletic SZ; Martin PJ; Storer BE; Inamoto Y; Chai X; Flowers MED; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):710-716. PubMed ID: 26475726
[TBL] [Abstract][Full Text] [Related]
11. Value of Screening Spirometry for Early Diagnosis of Bronchiolitis Obliterans Syndrome in Children After Allogeneic Hematopoietic Stem Cell Transplantation.
Yoon JS; Chun YH; Lee JW; Chung NG; Cho B
J Pediatr Hematol Oncol; 2015 Nov; 37(8):e462-7. PubMed ID: 26334431
[TBL] [Abstract][Full Text] [Related]
12. Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation.
Cheng GS; Bondeelle L; Gooley T; He Q; Jamani K; Krakow EF; Flowers MED; de Latour RP; Michonneau D; Socié G; Chien JW; Chevret S; Bergeron A
Biol Blood Marrow Transplant; 2020 Feb; 26(2):392-400. PubMed ID: 31682980
[TBL] [Abstract][Full Text] [Related]
13. Risk Factor and Clinical Outcome of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Rhee CK; Ha JH; Yoon JH; Cho BS; Min WS; Yoon HK; Lee JW
Yonsei Med J; 2016 Mar; 57(2):365-72. PubMed ID: 26847288
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions.
Hefazi M; Langer KJ; Khera N; Adamski J; Roy V; Winters JL; Gastineau DA; Jacob EK; Kreuter JD; Gandhi MJ; Hogan WJ; Litzow MR; Hashmi SK; Yadav H; Iyer VN; Scott JP; Wylam ME; Cartin-Ceba R; Patnaik MM
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1906-1913. PubMed ID: 29679771
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome.
Yates B; Murphy DM; Forrest IA; Ward C; Rutherford RM; Fisher AJ; Lordan JL; Dark JH; Corris PA
Am J Respir Crit Care Med; 2005 Sep; 172(6):772-5. PubMed ID: 15976371
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplantation.
Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
Chin Med J (Engl); 2013 Jul; 126(13):2489-94. PubMed ID: 23823823
[TBL] [Abstract][Full Text] [Related]
17. Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation.
Gao F; Chen J; Wei D; Wu B; Zhou M
Front Med; 2018 Apr; 12(2):224-228. PubMed ID: 28752350
[TBL] [Abstract][Full Text] [Related]
18. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.
Inamoto Y; Martin PJ; Onstad LE; Cheng GS; Williams KM; Pusic I; Ho VT; Arora M; Pidala J; Flowers MED; Gooley TA; Lawler RL; Hansen JA; Lee SJ
Transplant Cell Ther; 2021 Sep; 27(9):759.e1-759.e8. PubMed ID: 34126278
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.
Alkhunaizi M; Patel B; Bueno L; Bhan N; Ahmed T; Arain MH; Saliba R; Rondon G; Dickey BF; Bashoura L; Ost DE; Li L; Wang S; Shpall E; Champlin RE; Mehta R; Popat UR; Hosing C; Alousi AM; Sheshadri A
Transplant Cell Ther; 2023 Mar; 29(3):204.e1-204.e7. PubMed ID: 36503180
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.
Abedin S; Yanik GA; Braun T; Pawarode A; Magenau J; Goldstein SC; Levine JE; Kitko CL; Couriel DR
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1127-31. PubMed ID: 25687798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
